Edel del
Barco Morillo
Hospital Clinic Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (12)
2022
-
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
Journal of Clinical Oncology, Vol. 71
-
Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer
Oral Oncology, Vol. 134
-
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
Journal for immunotherapy of cancer, Vol. 10, Núm. 9
2021
-
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 8
-
Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy
Clinical Cancer Research, Vol. 27, Núm. 21, pp. 5878-5890
2020
-
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422
2018
-
SEOM clinical guideline in nasopharynx cancer (2017)
Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 84-88
2017
-
Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study
International Journal of Radiation Oncology Biology Physics, Vol. 97, Núm. 3, pp. 473-480
2016
-
A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients with Unresectable Squamous Cell Carcinoma of the Head and Neck
International Journal of Radiation Oncology Biology Physics, Vol. 94, Núm. 2, pp. 289-296
2013
-
Dolor como factor predictor de depresión en el paciente oncológico: estudio de casos y controles. Estudio D-PRESS
Revista de la Sociedad Espanola del Dolor, Vol. 20, Núm. 3, pp. 113-121
-
SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013
Clinical and Translational Oncology, Vol. 15, Núm. 12, pp. 1018-1024
-
SEOM clinical guidelines for the treatment of nasopharyngeal carcinoma 2013
Clinical and Translational Oncology, Vol. 15, Núm. 12, pp. 1025-1029